The RELATIVITY-047 trial has redefined first-line treatment paradigms in advanced melanoma (AM) through dual immune checkpoint inhibition targeting lymphocyte-activation gene 3 (LAG-3) and programmed death-1 (PD-1). This phase 2/3 randomised study demonstrated statistically superior progression-free survival (PFS) with the fixed-dose combination (FDC) of nivolumab (480 mg) plus relatlimab (160 mg) administered intravenously every 4 weeks compared to nivolumab monotherapy, establishing a new standard with durable clinical benefit confirmed through 4-year follow-up. 1-3 As you read further, this newsletter examines how nivolumab plus relatlimab is influencing the future direction of first-line melanoma therapy ##References## Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
N Engl J Med. 2022;386(1):24-34. Tawbi HA, Hodi…
